Compare Stocks → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. CVE:MPHNASDAQ:ORPH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMPHMedicureC$1.11+1.8%C$1.07C$0.92▼C$1.80C$11.59M1.015,099 shs600 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMPHMedicure+0.93%+5.83%+1.87%-3.54%-1.80%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%The only AI company to buy (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMPHMedicureN/AN/AN/AN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMPHMedicureN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMPHMedicureC$21.69M0.53C$0.45 per share2.49C$1.91 per share0.58ORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMPHMedicureC$1.08M-C$0.09N/A∞N/A-4.25%-4.51%-1.84%7/26/2024 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ALatest POLB, ORPH, SCLP, and MPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/8/2024Q4 2023MPHMedicureN/A-C$0.14-C$0.14-C$0.14N/AC$5.07 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMPHMedicureN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMPHMedicure2.731.921.29ORPHOrphazyme A/S0.141.80N/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipMPHMedicure23.10%ORPHOrphazyme A/S10.74%Insider OwnershipCompanyInsider OwnershipMPHMedicure26.68%ORPHOrphazyme A/SN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMPHMedicureN/A10.44 millionN/ANot OptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionablePOLB, ORPH, SCLP, and MPH HeadlinesRecent News About These CompaniesMay 28, 2024 | livescience.comRamesses II's sarcophagus finally identified thanks to overlooked hieroglyphicsMay 28, 2024 | msn.comResearchers identify novel way to potentially slow down or halt Alzheimer’s progressionMay 22, 2024 | reuters.comOtsuka to stop development of Alzheimer's disease drugMay 22, 2024 | msn.comThe EPA Cop Who Became a Warrior for ‘Forever Chemicals’May 7, 2024 | foxnews.comSome Alzheimer's cases may be caused by copies of a single gene, research showsMay 7, 2024 | nytimes.comStudy Suggests Genetics as a Cause, Not Just a Risk, for Some Alzheimer’sMay 7, 2024 | abcnews.go.comA gene long thought to just raise the risk for Alzheimer's may cause some casesMay 6, 2024 | orlandosentinel.comA subset of Alzheimer’s cases may be caused by two copies of a single gene, new research showsMay 6, 2024 | msn.comGenes known to increase the risk of Alzheimer’s may actually be an inherited form of the disorder, researchers sayMay 6, 2024 | msn.comScientists may have found a way to make a universal donor bloodMay 3, 2024 | yahoo.comAllozymes puts its accelerated enzymatics to work on a data and AI play, raising $15MMay 3, 2024 | alzheimersnewstoday.comBiomarker test to ID Alzheimer’s wins FDA breakthrough designationMay 2, 2024 | msn.comRapamycin shows promise in slowing Alzheimer's disease progression linked to seizuresMay 1, 2024 | msn.comOrgan transplant drug may slow Alzheimer's disease progressionMay 1, 2024 | fiercepharma.comFTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA databaseApril 30, 2024 | kfgo.comNeurocrine Biosciences’ Huntington’s disease drug gets FDA approvalApril 30, 2024 | dotesports.comOrisa, Venture hit with nerfs in Overwatch 2’s latest balance patchApril 30, 2024 | msn.comStrategic Innovation in SARMs: OTR-AC's Esterification AdvantageApril 30, 2024 | biospace.comEnlaza Raises $100M in Series A Financing Led by JP Morgan’s Life Sciences GroupApril 27, 2024 | msn.comOrpheus Pledger was on SAS Australia for a 'redemption arc'. Now there's been a manhunt for him.Media Sentiment Over TimeCompany DescriptionsMedicureCVE:MPHMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Orphazyme A/SNASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
